Current management of diabetes patients with COVID-19

References

• Steenblock C, Schwarz PEH, Ludwig B, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9:786–798.
   PubMed Web of Science ®Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 Jul;26(7):1017–1032.
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020 May 9;395(10235):1517–1520.
   PubMed Web of Science ®Google Scholar
• Casas-Rojo JM, Anton-Santos JM, Millan-Nunez-Cortes J, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry. Rev Clin Esp. 2020;220:480–494.
   PubMed Web of Science ®Google Scholar
• Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22:1915–1924.
   PubMed Web of Science ®Google Scholar
• Roncon L, Zuin M, Rigatelli G, et al. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354.
   PubMed Web of Science ®Google Scholar
• Corona G, Pizzocaro A, Vena W, et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis. Rev Endocr Metab Disor. 2021;22:275–296.
   Google Scholar
• Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:382–386.
   PubMed Web of Science ®Google Scholar
• Bambra C, Riordan R, Ford J, et al. The COVID-19 pandemic and health inequalities. J Epidemiol Community Health. 2020;74(11):964–968.
   PubMed Web of Science ®Google Scholar
• Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423–441.
   PubMed Web of Science ®Google Scholar
• Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–833.
   PubMed Web of Science ®Google Scholar
• Lazarus G, Audrey J, Wangsaputra VK, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: a systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2020;171:108561.
   PubMed Web of Science ®Google Scholar
• Mittal J, Ghosh A, Bhatt SP, et al. High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: a case-control study. Diabetes Metab Syndr. 2021;15:102302.
   PubMedGoogle Scholar
• Raveendran AV, Misra A. Post COVID-19 syndrome (“Long COVID”) and diabetes: challenges in diagnosis and management. Diabetes Metab Syndr. 2021;15:102235.
   PubMed Web of Science ®Google Scholar
• Catriona C, Paolo P. SARS-CoV-2 induced post-translational protein modifications: a trigger for developing autoimmune diabetes? Diabetes Metab Res Rev. 2022;38:e3508.
   PubMed Web of Science ®Google Scholar
• Montefusco L, Ben Nasr M, D’Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3:774–785.
   PubMedGoogle Scholar
• Laurenzi A, Caretto A, Molinari C, et al. No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021;107:e1009–19.
   Web of Science ®Google Scholar
• Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: a systematic review and meta-analysis. Prim Care Diabetes. 2022 Aug;16(4):591–593.
   PubMed Web of Science ®Google Scholar
• Pasrija R, Naime M. Resolving the equation between mucormycosis and COVID-19 disease. Mol Biol Rep. 2022;49:3349–3356.
   PubMed Web of Science ®Google Scholar
• Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186:289–298.
   Google Scholar
• Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021;64:1452–1459.
   PubMed Web of Science ®Google Scholar
• Sen M, Lahane S, Lahane TP, et al. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69:244–252.
   PubMed Web of Science ®Google Scholar
• Divakar PK. Fungal taxa responsible for mucormycosis/”black fungus” among COVID-19 patients in India. J Fungi (Basel). 2021;7:641.
   PubMedGoogle Scholar
• Ravani SA, Agrawal GA, Leuva PA, et al. Rise of the Phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69:1563–1568.
   PubMed Web of Science ®Google Scholar
• Kumar M, Sarma DK, Shubham S, et al. Mucormycosis in COVID-19 pandemic: risk factors and linkages. Curr Res Microb Sci. 2021;2:100057.
   PubMedGoogle Scholar
• Donath MY, Shoelson SE. Type 2 Diabetes as an Inflammatory Disease. Nat Rev Immunol. 2011;11(2):98–107.
   PubMed Web of Science ®Google Scholar
• Diabetes KS. Infection: is There a Link? - A Mini-Review. Gerontology. 2013;59(2):99–104.
   PubMed Web of Science ®Google Scholar
• Grossmann V, Schmitt VH, Zeller T, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2015;38(7):1356–1364.
   PubMed Web of Science ®Google Scholar
• Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(7):S27–36.
   PubMedGoogle Scholar
• Kim JH, Park K, Lee SB, et al. Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. J Diabetes Invest. 2019;10(5):1223–1228.
   PubMed Web of Science ®Google Scholar
• Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and Insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6:a009191.
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–150.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Rubino F, Ludwig B, et al. Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nat Metab. 2021;3:289–292.
   PubMedGoogle Scholar
• Santos A, Magro DO, Evangelista-Poderoso R, et al. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13:23.
   PubMed Web of Science ®Google Scholar
• Langouche L, Van den Berghe G, Gunst J. Hyperglycemia and insulin resistance in COVID-19 versus non-COVID critical illness: are they really different? Crit Care. 2021;25:437.
   PubMed Web of Science ®Google Scholar
• Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284.
   PubMed Web of Science ®Google Scholar
• Stefan N. SARS-CoV-2 fires up inflammation in adipose tissue. Nat Rev Endocrinol. 2023 Jan;19(1):8–9.–96.
   PubMedGoogle Scholar
• Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022 Feb;18(2):75–76.
   PubMed Web of Science ®Google Scholar
• Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021 Mar;17(3):135–149.
   PubMed Web of Science ®Google Scholar
• Perez A, Jansen-Chaparro S, Saigi I, et al. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6:9–20.
   PubMed Web of Science ®Google Scholar
• Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69:2048–2053.
   PubMed Web of Science ®Google Scholar
• Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, et al. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6:1073–1081.
   PubMedGoogle Scholar
• Kumar R, Misra AK, Dutta S, et al. A systematic review of mucormycosis cases in COVID-19: is it an unholy trilogy of COVID-19, diabetes mellitus, and corticosteroids? J Family Med Prim Care. 2022 Jun;11(6):2573–2580.
   PubMedGoogle Scholar
• Singh AK, Gupta R, Ghosh A, et al. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303–310.
   PubMed Web of Science ®Google Scholar
• Fleming N, Sacks LJ, Pham CT, et al. An overview of COVID-19 in people with diabetes: pathophysiology and considerations in the inpatient setting. Diabetes Med. 2021;38(3):e14509.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003;2(2):95–108.
   PubMedGoogle Scholar
• Corrao S, Pinelli K, Vacca M, et al. Type 2 diabetes mellitus and COVID-19: a narrative review. Front Endocrinol (Lausanne). 2021 Mar 31;12:609470.
   PubMedGoogle Scholar
• Pelle MC, Zaffina I, Provenzano M, et al. COVID-19 and diabetes-Two giants colliding: from pathophysiology to management. Front Endocrinol (Lausanne). 2022 Aug 19;13:974540.
   PubMed Web of Science ®Google Scholar
• Kazakou P, Paschou SA, Psaltopoulou T, et al. A. Early and late endocrine complications of COVID-19. Endocr. Connect. 2021;10:R229–39.
   Google Scholar
• Maddaloni E, D’Onofrio L, Alessandri F, et al. Clinical features of patients with type 2 diabetes with and without covid-19: a case control study (CoViDiab I). Diabetes Res Clin Pract. 2020;169:108454.
   PubMed Web of Science ®Google Scholar
• Roca-Ho H, Riera M, Palau V, et al. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18(3):563.
   PubMed Web of Science ®Google Scholar
• Galindo RJ, Aleppo G, Klonoff DC, et al. Implementation of continuous glucose monitoring in the hospital: emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J Diabetes Sci Technol. 2020;14:822–832.
   PubMedGoogle Scholar
• Davis GM, Faulds E, Walker T, et al. Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: proof of concept. Diabetes Care. 2021;44:1055–1058.
   PubMed Web of Science ®Google Scholar
• Yu B, Li C, Sun Y, et al. Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes. Cell Metab. 2020;33:65–77.
   PubMed Web of Science ®Google Scholar
• Yang Y, Cai Z, Zhang J. Insulin treatment may increase adverse outcomes in patients with COVID-19 and diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:696087.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43:399–1407.
   Web of Science ®Google Scholar
• Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546–550.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Coronavirus infections and type 2 diabetes—Shared pathways with therapeutic implications. Endocr Rev. 2020;41:457–470.
   Web of Science ®Google Scholar
• Li Y, Yang X, Yan P, et al. Metformin in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:704666.
   PubMedGoogle Scholar
• Bailey CJ, Gwilt M. Diabetes, metformin and the clinical course of covid-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin. Front Pharmacol. 2022;13:784459.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dong J, Martin M, et al. AMP activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension. Am J Respir Crit Care Med. 2018;198(4):509–520.
   PubMed Web of Science ®Google Scholar
• Ursini F, Ciaffi J, Landini MP, et al. COVID-19 and diabetes: is metformin a friend or foe? Diabetes Res Clin Pract. 2020;164:108167.
   PubMed Web of Science ®Google Scholar
• Park JW, Lee JH, Park YH, et al. Sex dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. World J Gastroenterol. 2017;23(28):5196–5205.
   PubMed Web of Science ®Google Scholar
• Tsaknis G, Siempos II, Kopterides P, et al. Metformin attenuates ventilator-induced lung injury. Crit Care. 2012;16:R134.
   PubMed Web of Science ®Google Scholar
• Oh TK, Song IA. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Acta Diabetol. 2021;58:771–778.
   PubMedGoogle Scholar
• Crouse AB, Grimes T, Li P, et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne). 2020;11:600439.
   PubMed Web of Science ®Google Scholar
• Ganesh A, Randall MD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:2642–2656.
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290.
   Google Scholar
• Smati S, Tramunt B, Wargny M, et al. COVID-19 and diabetes outcomes: rationale for and updates from the CORONADO study. Curr Diab Rep. 2022;22:53–63.
   PubMed Web of Science ®Google Scholar
• Li J, Wei Q, McCowen KC, et al. Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus. Endocrinol Diabetes Metab. 2022;5(1):e00301.
   PubMedGoogle Scholar
• Scheen AJ. Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes Metab. 2020;46(6):423–426.
   PubMed Web of Science ®Google Scholar
• Wang J, Cooper JM, Gokhale K, et al. Association of metformin with susceptibility to covid-19 in people with type 2 diabetes. J Clin Endocrinol Metab. 2021;106(5):1255–1268.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–33.
   PubMedGoogle Scholar
• Lv W, Wang X, Xu Q, et al. Mechanisms and characteristics of sulfonylureas and glinides. Curr Top Med Chem. 2020;20:37–56.
   PubMed Web of Science ®Google Scholar
• Chee YJ, Tan SK, Yeoh E. Dissecting the interaction between COVID-19 and diabetes mellitus. J Diabetes Investig. 2020;11(5):1104–1114.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.
   PubMed Web of Science ®Google Scholar
• Li AC, Brown KK, Silvestre MJ, et al. Peroxisome Proliferator-Activated Receptor g Ligands Inhibit Development of Atherosclerosis in LDL Receptor-Deficient Mice. J Clin Invest. 2000;106(4):523–531.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone After Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321–1331.
   PubMed Web of Science ®Google Scholar
• Bielka W, Przezak A, Pawlik A. Therapy of type 2 diabetes in patients with SARS-CoV-2 infection. Int J Mol Sci. 2021;22(14):7605.
   PubMed Web of Science ®Google Scholar
• Mulvihill EE. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: control of the incretin axis and regulation of postprandial glucose and lipid metabolism. Peptides. 2018;100:158–164.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Doumas M. Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies. Endocrinol Metab. 2021;36:904–908.
   Google Scholar
• Kawasaki T, Chen W, Htwe YM, et al. DPP4 Inhibition by Sitagliptin Attenuates LPS-Induced Lung Injury in Mice. Am J Physiol Lung Cell Mol Physiol. 2018;315(5):L834–45.
   PubMed Web of Science ®Google Scholar
• Iacobellis G. COVID-19 and Diabetes: can DPP4 Inhibition Play a Role? Diabetes Res Clin Pract. 2020;162:108125.
   PubMed Web of Science ®Google Scholar
• Vankadari N, Wilce JA. Emerging COVID-19. Coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9(1):601–604.
   PubMed Web of Science ®Google Scholar
• Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the middle east respiratory syndrome coronavirus. J Virol. 2014;88(3):1834–1838.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z, Yang L, et al. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. iScience. 2020;23(6):101160.
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl Peptidase 4 Is a Functional Receptor for the Emerging Human Coronavirus-EMC. Nature. 2013;495(7440):251–254.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Morieri ML, Longato E, et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study. Diabetes Obes Metab. 2020;22(10):1946–1950.
   PubMed Web of Science ®Google Scholar
• Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500–1515.
   PubMed Web of Science ®Google Scholar
• Lim S, Oh TJ, Dawson J, et al. Diabetes Drugs and Stroke Risk: intensive Versus Conventional Glucose-Lowering Strategies, and Implications of Recent Cardiovascular Outcome Trials. Diabetes Obes Metab. 2020;22(1):6–15.
   PubMed Web of Science ®Google Scholar
• Lim S, Lee GY, Park HS, et al. Attenuation of Carotid Neointimal Formation After Direct Delivery of a Recombinant Adenovirus Expressing Glucagon-Like Peptide-1 in Diabetic Rats. Cardiovasc Res. 2017;113(2):183–194.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metab. 2018;27(4):740–756.
   PubMed Web of Science ®Google Scholar
• Toki S, Goleniewska K, Reiss S, et al. Glucagon-Like Peptide 1 Signaling Inhibits Allergen-Induced Lung IL-33 Release and Reduces Group 2 Innate Lymphoid Cell Cytokine Production In Vivo. J Allergy Clin Immunol. 2018;142(5):1515–28.e8.
   PubMed Web of Science ®Google Scholar
• Nyland JE, Raja-Khan NT, Bettermann K, et al. Diabetes, drug treatment, and mortality in COVID-19: a multinational retrospective cohort study. Diabetes. 2021;70(12):2903–2916.
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Intan D, Hananto JE, et al. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021;179:109031.
   PubMed Web of Science ®Google Scholar
• Popovic DS, Papanas N, Pantea Stoian A, et al. Use of novel antidiabetic agents in patients with type 2 diabetes and COVID-19: a critical review. Diabetes Ther. 2021;12(12):3037–3054.
   PubMed Web of Science ®Google Scholar
• Lim S, Bae JH, Kwon H-S, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2020;17:11–30.
   PubMed Web of Science ®Google Scholar
• Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020;163:108146.
   PubMed Web of Science ®Google Scholar
• Cure E, Cumhur Cure M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr. 2020;14(4):349–350.
   PubMed Web of Science ®Google Scholar
• Hahn K, Ejaz AA, Kanbay M, et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711–712.
   PubMed Web of Science ®Google Scholar
• Vitale RJ, Valtis YK, McDonnell ME, et al. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors. AACE Clin Case Rep. 2021;7(1):10–13.
   PubMedGoogle Scholar
• Palermo NE, Sadhu AR, McDonnell ME. Diabetic Ketoacidosis in COVID-19: unique Concerns and Considerations. J Clin Endocrinol Metab. 2020;105(8):2819–2829.
   Web of Science ®Google Scholar
• Pal R, Sachdeva N, Mukherjee S, et al. Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: a preliminary report. Diabetes Metab Syndr. 2021;15(1):193–196.
   PubMed Web of Science ®Google Scholar
• Lampasona V, Secchi M, Scavini M, et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020;63(12):2548–2558.
   PubMed Web of Science ®Google Scholar
• Marfella R, D’Onofrio N, Sardu C, et al. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes Metab. 2022;24(1):160–165.
   PubMed Web of Science ®Google Scholar
• Sourij C, Tripolt NJ, Aziz F, et al. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022;24(5):849–858.
   PubMed Web of Science ®Google Scholar
• Soetedjo NNM, Iryaningrum MR, Lawrensia S, et al. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: a systematic review. Diabetes Metab Syndr. 2022;16(2):102406.
   PubMed Web of Science ®Google Scholar
• Khunti K, Valabhji J, Misra S. Diabetes and the COVID-19 pandemic. Diabetologia. 2023 Feb;66(2):255–266.
   PubMed Web of Science ®Google Scholar
• Kazakou P, Lambadiari V, Ikonomidis I, et al. Diabetes and COVID-19; A Bidirectional Interplay. Front Endocrinol (Lausanne). 2022 Feb 17;13:780663.
   PubMed Web of Science ®Google Scholar
• Lambadiari V, Mitrakou A, Kountouri A, et al. Association of COVID-19 With Impaired Endothelial Glycocalyx, Vascular Function and Myocardial Deformation 4 Months After Infection. Eur J Heart Fail. 2021;23(11):1916–1926.
   PubMed Web of Science ®Google Scholar
• Rizvi AA, Kathuria A, Al Mahmeed W, et al. Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022 Nov;36(11):108336.
   PubMed Web of Science ®Google Scholar